Enliven Therapeutics, Inc. (ELVN)
54.32
-1.91
(-3.40%)
USD |
NASDAQ |
Sep 11, 16:00
54.29
-0.03
(-0.06%)
After-Hours: 20:00
Enliven Therapeutics Debt to Equity Ratio : 0.0017 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.0017 |
| March 31, 2026 | 0.0007 |
| December 31, 2025 | 0.0009 |
| September 30, 2025 | 0.0008 |
| June 30, 2025 | 0.0008 |
| March 31, 2025 | 0.0013 |
| December 31, 2024 | 0.00 |
| September 30, 2024 | 0.0003 |
| June 30, 2024 | 0.0006 |
| March 31, 2024 | 0.0008 |
| December 31, 2023 | 0.0014 |
| September 30, 2023 | 0.0016 |
| June 30, 2023 | 0.0018 |
| March 31, 2023 | 0.0019 |
| Date | Value |
|---|---|
| December 31, 2022 | 0.00 |
| September 30, 2022 | 0.00 |
| June 30, 2022 | 0.0073 |
| March 31, 2022 | 0.0342 |
| December 31, 2021 | 0.0076 |
| September 30, 2021 | 0.0072 |
| June 30, 2021 | 0.012 |
| March 31, 2021 | 0.0112 |
| December 31, 2020 | 0.00 |
| September 30, 2020 | 0.00 |
| June 30, 2020 | 0.00 |
| March 31, 2020 | 0.00 |
| December 31, 2019 | 0.00 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Cocrystal Pharma, Inc. | 1.284 |
| CNBX Pharmaceuticals, Inc. | -0.4388 |
| GB Sciences, Inc. | -- |
| Arvinas, Inc. | 0.0146 |
| Fulcrum Therapeutics, Inc. | 0.017 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 910.22M |
| Total Liabilities (Quarterly) | 15.07M |
| Shareholders Equity (Quarterly) | 895.15M |
| Current Ratio | 64.07 |
| Net Debt Paydown Yield | -0.01% |